A New Era for the Systemic Therapy of Neuroendocrine Tumors

03/28/2012 - 03/28/2014

This is an Oncologist CME Online, released on March 28, 2012, expiring on March 28, 2014.

The learning objectives are:

  1. Describe the underlying biology of neuroendocrine tumors including pancreatic neuroendocrine tumors (PNETs) and carcinoids and the importance of these biologic features in the evolution of new drugs for these diseases.
  2. Cite the historical data regarding the use of cytotoxic agents in the treatment of pancreatic neuroendocrine tumors and carcinoids.
  3. Explain the significance of recent clinical trials utilizing biologic agents, in particular octreotide, the small molecule tyrosine kinase inhibitor, sunitinib and the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and how these medications have altered the natural history of both pancreatic neuroendocrine tumors and carcinoids.

ACCREDITATION and CREDIT DESIGNATION

The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.

The Society for Translational Oncology designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CLICK HERE for further information.

Print Friendly, PDF & Email